Exact Mass: 560.2419772000001
Exact Mass Matches: 560.2419772000001
Found 500 metabolites which its exact mass value is equals to given mass value 560.2419772000001
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Chloramphenicol palmitate
C27H42Cl2N2O6 (560.2419772000001)
C254 - Anti-Infective Agent > C258 - Antibiotic Same as: D01072
Isomorellic acid
Morellic acid is found in fruits. Morellic acid is from Garcinia morella (batuan Isomorellic acid is a member of pyranoxanthones. Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity[1]. Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity[1].
Chloramphenicol palmitate
C27H42Cl2N2O6 (560.2419772000001)
Quizartinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Cyclo((2R)-2-aminobutanoyl-N2-methyl-L-arginylglycyl-L-alpha-aspartyl-3-(aminomethyl)benzoyl)
Sotorasib
D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors[1][2]. Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].
morellic acid
A dioxo monocarboxylic acid derived from morellin by oxidation of the aldehyde group to the corresponding carboxy group. Isolated from Garcinia morella and Garcinia hanburyi, it exhibits antineoplastic, antibacterial and anti-HIV activity. Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity[1]. Morellic acid is isolated from Garcinia Morella with an antiangiogenic activity[1].
Methyl (2R)-[(1S,2R,4S,5R,9R,10R,13R,14S,15S,17S)-17-acetoxy-9-(3-furyl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.02,4 04,13 05,10]octadec-15-yl](hydroxy)acetate
5alpha-acetoxy-20-(benzoyloxy)-2alpha,4alpha,7beta,9alpha,15-pentahydroxy-10-oxo-10,19-epoxy-11(15->1)abeo-tax-11(12)-ene|taiwantaxin B
12-Oxo-2beta-O-acetyl-3beta-O-isobutyryl-5beta,11alpha-dihydroxybufalin
4beta,15-dihydro-3beta-acetoxy-8beta-5(5-acetoxytigloyl)-4-hydroxytigloyloxyzaluzanin C|4beta,15-dihydro-3beta-acetoxy-8beta-5<5-acetoxytigloyl>-4-hydroxytigloyloxyzaluzanin C
11alpha-hydroxy-scilliglaucosidin-3-O-alpha-L-rhamnoside
Scilliglaucosidin-alpha-D-glucosid, Scilliglaucosid
20-acetoxy-2alpha-benxyloxy-4alpha,5alpha,7beta,9alpha,13alpha-pentahydroxy-11(15-1),11(10-9)bisabeotax-11-eno-10,15-lactone
(3R,3aR,5aS,6S,7aR,8S,9S,11S,13aS,14aR)-dodecahydro-3,8,9-trihydroxy-5,5,11-trimethyl-11-[(2S,3Z)-2-methyl-3-(4-methyl-5-oxofuran-2(5H)-ylidene)propanoyl]-2H,5H-6,8:9,13a-diepoxycycloocta[5,6]cyclohepta[1,2-c]furo[3,2-b]furan-2(14H)-one|schicagenin E
rel-(2R,3S,5S,1S,3R)-2,5,1,3-tetra(4-hydroxyphenyl)-4-methylene-4,5,3,4,6,7-hexahydro-1H,2H-spiro[furan-3,5-isobenzofuran]|ribesin H
12-oxo-hellebrigenin-3-O-4,6-dideoxy-alpha-L-ribohexopyranoside|kalanchoside C
1beta-O-beta-D-glucopyranosyl-15-O-(p-hydroxyphenylacetyl)-5alpha,6betaH-eudesma-3,11(13)-dien-12,6alpha-olide
1,3,6-Tri(4-hydroxybenzyl)-4-methoxy-9,10-dihydrophenanthrene-2,7-diol
(rel-3R,3aS,4aR,5aS,7aS,8aR,11aR,13aS,15R,15aR,17S,17aS,17bS,17cS)-tetradecahydro-15,17-dihydroxy-3,4a,5a,13,13-pentamethyl-8H-7a,17-epoxy-10H-furo[3,2-b]furo[3,2:2,3]furo[3,4: 4,5]cyclohepta[1,2: 5,6]cycloocta[1,2:4,5]cyclopenta[1,2-d]furan-2,5,10,16-(3H,7H,13H)-tetrone|lancifodilactone R
(19Xi)-19,20-epoxy-2,10-dihydroxy-4-methyl-16-(3t-phenyl-acryloyloxymethyl)-(2alpha,20betaH)-1,2,19,20-tetrahydro-4,5-seco-akuammilane-5,17-dioic acid 5->2-lactone 17-methyl ester|10-Hydroxy-lanciferin|10-hydroxy-lanciferine
(19Xi)-19,20-epoxy-2,10-dihydroxy-4-methyl-16-(3t-phenyl-acryloyloxymethyl)-(2alpha,20betaH)-1,2,19,20-tetrahydro-4,5-seco-akuammilane-5,17-dioic acid 5->2-lactone 17-methyl ester|10-hydroxy-lanciferine|10-Hydroxylanciferin
3-O-beta-D-glucopyranosyl-14-O-(p-hydroxyphenylacetyl)-3beta,14-dihydroxycostunolide
Tyr His Ile Glu
His Glu Phe Glu
C29H36O11_7,11-Methano-2H,4H-oxireno[1,8]cycloocta[1,2-f][2]benzopyran-8-acetic acid, 10-(acetyloxy)-4-(3-furanyl)dodecahydro-alpha,11-dihydroxy-4a,7,9,9-tetramethyl-2,13-dioxo-, methyl ester, (alphaR,4R,4aR,7S,8S,10S,11S,11aR,12aS)
methyl (2R)-2-[(1S,2R,4S,9R,10R,14S,15S,17S)-17-(acetyloxy)-9-(furan-3-yl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-15-yl]-2-hydroxyacetate
methyl (2R)-2-[(1S,2R,4S,9R,10R,14S,15S,17S)-17-(acetyloxy)-9-(furan-3-yl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,⁴.0⁴,¹³.0⁵,¹⁰]octadecan-15-yl]-2-hydroxyacetate_major
methyl (2R)-2-[(1S,2R,4S,9R,10R,14S,15S,17S)-17-(acetyloxy)-9-(furan-3-yl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.0²,?.0?,¹³.0?,¹?]octadecan-15-yl]-2-hydroxyacetate
Cys Ile Tyr Tyr
Cys Leu Tyr Tyr
Cys Pro Arg Trp
Cys Pro Trp Arg
Cys Arg Pro Trp
Cys Arg Trp Pro
Cys Trp Pro Arg
Cys Trp Arg Pro
Cys Tyr Ile Tyr
Cys Tyr Leu Tyr
Cys Tyr Tyr Ile
Cys Tyr Tyr Leu
Asp Asp Arg Arg
Asp Ile Gln Trp
Asp Ile Trp Gln
Asp Leu Gln Trp
Asp Leu Trp Gln
Asp Gln Ile Trp
Asp Gln Leu Trp
Asp Gln Trp Ile
Asp Gln Trp Leu
Asp Arg Asp Arg
Asp Arg Arg Asp
Asp Trp Ile Gln
Asp Trp Leu Gln
Asp Trp Gln Ile
Asp Trp Gln Leu
Glu Glu Phe His
Glu Glu His Phe
Glu Glu Gln Arg
Glu Glu Arg Gln
Glu Phe Glu His
Glu Phe His Glu
Glu His Glu Phe
Glu His Phe Glu
Glu His Ile Tyr
Glu His Leu Tyr
Glu His Tyr Ile
Glu His Tyr Leu
Glu Ile His Tyr
Glu Ile Asn Trp
Glu Ile Trp Asn
Glu Ile Tyr His
Glu Leu His Tyr
Glu Leu Asn Trp
Glu Leu Trp Asn
Glu Leu Tyr His
Glu Asn Ile Trp
Glu Asn Leu Trp
Glu Asn Trp Ile
Glu Asn Trp Leu
Glu Gln Glu Arg
Glu Gln Arg Glu
Glu Gln Val Trp
Glu Gln Trp Val
Glu Arg Glu Gln
Glu Arg Gln Glu
Glu Val Gln Trp
Glu Val Trp Gln
Glu Trp Ile Asn
Glu Trp Leu Asn
Glu Trp Asn Ile
Glu Trp Asn Leu
Glu Trp Gln Val
Glu Trp Val Gln
Glu Tyr His Ile
Glu Tyr His Leu
Glu Tyr Ile His
Glu Tyr Leu His
Phe Glu Glu His
Phe Glu His Glu
Phe Phe Phe Thr
Phe Phe Thr Phe
Phe His Glu Glu
Phe Met Thr Tyr
Phe Met Tyr Thr
Phe Thr Phe Phe
Phe Thr Met Tyr
Phe Thr Tyr Met
Phe Tyr Met Thr
Phe Tyr Thr Met
His Glu Glu Phe
His Glu Ile Tyr
His Glu Leu Tyr
His Glu Tyr Ile
His Glu Tyr Leu
His Phe Glu Glu
His His His Met
His His Met His
His Ile Glu Tyr
His Ile Tyr Glu
His Leu Glu Tyr
His Leu Tyr Glu
His Met His His
His Asn Gln Tyr
His Asn Tyr Gln
His Gln Asn Tyr
His Gln Tyr Asn
His Tyr Glu Ile
His Tyr Glu Leu
His Tyr Ile Glu
His Tyr Leu Glu
His Tyr Asn Gln
His Tyr Gln Asn
Ile Cys Tyr Tyr
Ile Asp Gln Trp
Ile Asp Trp Gln
Ile Glu His Tyr
Ile Glu Asn Trp
Ile Glu Trp Asn
Ile Glu Tyr His
Ile His Glu Tyr
Ile His Tyr Glu
Ile Asn Glu Trp
Ile Asn Trp Glu
Ile Gln Asp Trp
Ile Gln Trp Asp
Ile Trp Asp Gln
Ile Trp Glu Asn
Ile Trp Asn Glu
Ile Trp Gln Asp
Ile Tyr Cys Tyr
Ile Tyr Glu His
Ile Tyr His Glu
Ile Tyr Tyr Cys
Leu Cys Tyr Tyr
Leu Asp Gln Trp
Leu Asp Trp Gln
Leu Glu His Tyr
Leu Glu Asn Trp
Leu Glu Trp Asn
Leu Glu Tyr His
Leu His Glu Tyr
Leu His Tyr Glu
Leu Asn Glu Trp
Leu Asn Trp Glu
Leu Gln Asp Trp
Leu Gln Trp Asp
Leu Trp Asp Gln
Leu Trp Glu Asn
Leu Trp Asn Glu
Leu Trp Gln Asp
Leu Tyr Cys Tyr
Leu Tyr Glu His
Leu Tyr His Glu
Leu Tyr Tyr Cys
Met Phe Thr Tyr
Met Phe Tyr Thr
Met His His His
Met Pro Gln Trp
Met Pro Trp Gln
Met Gln Pro Trp
Met Gln Trp Pro
Met Thr Phe Tyr
Met Thr Tyr Phe
Met Trp Pro Gln
Met Trp Gln Pro
Met Tyr Phe Thr
Met Tyr Thr Phe
Asn Glu Ile Trp
Asn Glu Leu Trp
Asn Glu Trp Ile
Asn Glu Trp Leu
Asn His Gln Tyr
Asn His Tyr Gln
Asn Ile Glu Trp
Asn Ile Trp Glu
Asn Leu Glu Trp
Asn Leu Trp Glu
Asn Asn Gln Trp
Asn Asn Trp Gln
Asn Gln His Tyr
Asn Gln Asn Trp
Asn Gln Trp Asn
Asn Gln Tyr His
Asn Trp Glu Ile
Asn Trp Glu Leu
Asn Trp Ile Glu
Asn Trp Leu Glu
Asn Trp Asn Gln
Asn Trp Gln Asn
Asn Tyr His Gln
Asn Tyr Gln His
Pro Cys Arg Trp
Pro Cys Trp Arg
Pro Met Gln Trp
Pro Met Trp Gln
Pro Gln Met Trp
Pro Gln Trp Met
Pro Arg Cys Trp
Pro Arg Trp Cys
Pro Trp Cys Arg
Pro Trp Met Gln
Pro Trp Gln Met
Pro Trp Arg Cys
Gln Asp Ile Trp
Gln Asp Leu Trp
Gln Asp Trp Ile
Gln Asp Trp Leu
Gln Glu Glu Arg
Gln Glu Arg Glu
Gln Glu Val Trp
Gln Glu Trp Val
Gln His Asn Tyr
Gln His Tyr Asn
Gln Ile Asp Trp
Gln Ile Trp Asp
Gln Leu Asp Trp
Gln Leu Trp Asp
Gln Met Pro Trp
Gln Met Trp Pro
Gln Asn His Tyr
Gln Asn Asn Trp
Gln Asn Trp Asn
Gln Asn Tyr His
Gln Pro Met Trp
Gln Pro Trp Met
Gln Arg Glu Glu
Gln Val Glu Trp
Gln Val Trp Glu
Gln Trp Asp Ile
Gln Trp Asp Leu
Gln Trp Glu Val
Gln Trp Ile Asp
Gln Trp Leu Asp
Gln Trp Met Pro
Gln Trp Asn Asn
Gln Trp Pro Met
Gln Trp Val Glu
Gln Tyr His Asn
Gln Tyr Asn His
Arg Cys Pro Trp
Arg Cys Trp Pro
Arg Asp Asp Arg
Arg Asp Arg Asp
Arg Glu Glu Gln
Arg Glu Gln Glu
Arg Pro Cys Trp
Arg Pro Trp Cys
Arg Gln Glu Glu
Arg Arg Asp Asp
Arg Trp Cys Pro
Arg Trp Pro Cys
Thr Phe Phe Phe
Thr Phe Met Tyr
Thr Phe Tyr Met
Thr Met Phe Tyr
Thr Met Tyr Phe
Thr Tyr Phe Met
Thr Tyr Met Phe
Val Glu Gln Trp
Val Glu Trp Gln
Val Gln Glu Trp
Val Gln Trp Glu
Val Trp Glu Gln
Val Trp Gln Glu
Trp Cys Pro Arg
Trp Cys Arg Pro
Trp Asp Ile Gln
Trp Asp Leu Gln
Trp Asp Gln Ile
Trp Asp Gln Leu
Trp Glu Ile Asn
Trp Glu Leu Asn
Trp Glu Asn Ile
Trp Glu Asn Leu
Trp Glu Gln Val
Trp Glu Val Gln
Trp Ile Asp Gln
Trp Ile Glu Asn
Trp Ile Asn Glu
Trp Ile Gln Asp
Trp Leu Asp Gln
Trp Leu Glu Asn
Trp Leu Asn Glu
Trp Leu Gln Asp
Trp Met Pro Gln
Trp Met Gln Pro
Trp Asn Glu Ile
Trp Asn Glu Leu
Trp Asn Ile Glu
Trp Asn Leu Glu
Trp Asn Asn Gln
Trp Asn Gln Asn
Trp Pro Cys Arg
Trp Pro Met Gln
Trp Pro Gln Met
Trp Pro Arg Cys
Trp Gln Asp Ile
Trp Gln Asp Leu
Trp Gln Glu Val
Trp Gln Ile Asp
Trp Gln Leu Asp
Trp Gln Met Pro
Trp Gln Asn Asn
Trp Gln Pro Met
Trp Gln Val Glu
Trp Arg Cys Pro
Trp Arg Pro Cys
Trp Val Glu Gln
Trp Val Gln Glu
Tyr Cys Ile Tyr
Tyr Cys Leu Tyr
Tyr Cys Tyr Ile
Tyr Cys Tyr Leu
Tyr Glu His Ile
Tyr Glu His Leu
Tyr Glu Ile His
Tyr Glu Leu His
Tyr Phe Met Thr
Tyr Phe Thr Met
Tyr His Glu Ile
Tyr His Glu Leu
Tyr His Leu Glu
Tyr His Asn Gln
Tyr His Gln Asn
Tyr Ile Cys Tyr
Tyr Ile Glu His
Tyr Ile His Glu
Tyr Ile Tyr Cys
Tyr Leu Cys Tyr
Tyr Leu Glu His
Tyr Leu His Glu
Tyr Leu Tyr Cys
Tyr Met Phe Thr
Tyr Met Thr Phe
Tyr Asn His Gln
Tyr Asn Gln His
Tyr Gln His Asn
Tyr Gln Asn His
Tyr Thr Phe Met
Tyr Thr Met Phe
Tyr Tyr Cys Ile
Tyr Tyr Cys Leu
Tyr Tyr Ile Cys
Tyr Tyr Leu Cys
Carbamic acid, 1,6-hexanediylbis-, bis(9H-fluoren-9-ylmethyl) ester
2-O-Methyl-5-O-DMT-Uridine;DMT-2-OMe-U
5’-O-(4,4’-Dimethoxytrityl)-2’-O-methyluridine is a uridine analog. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents[1].
9-[1,1-Biphenyl]-4-yl-9-phenyl-3,3-bi-9H-carbazole
9-[1,1-Biphenyl]-3-yl-9-phenyl-3,3-bi-9H-carbazole
[4-[(2-AMino-3-Methyl-1-oxobutyl)aMino]-2-hydroxy-5-phenyl-1-(phenylMethyl)pentyl]-carbaMic Acid 5-ThiazolylMethyl Ester Monohydrochloride
C28H37ClN4O4S (560.2223912000001)
3,3-(3,7,12,17-Tetramethyl-8,13-divinyl-2,18-porphyrindiyl)dipro panoate
C34H32N4O4 (560.2423431999999)
N-s-butyl-N-[(2R,3S)-3-({[(3aS,5R,6aR)-hexahydro-2H-cyclopenta[b]furan-5-yloxy]carbonyl}amino)-2-hydroxy-4-phenylbutyl]-4-(hydroxymethyl)benzenesulfonamide
3-[(3-Sec-butyl-4-hydroxybenzoyl)amino]azepan-4-YL 4-(2-hydroxy-5-methoxybenzoyl)benzoate
n-1,2,3,4-Tetrahydronaphth-1-yl-2-[3,5-dimethoxybenzamido]-2-deoxy-adenosine
Quizartinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Protoporphyrinate
C34H32N4O4-2 (560.2423431999999)
D011838 - Radiation-Sensitizing Agents > D017319 - Photosensitizing Agents COVID info from COVID-19 Disease Map D003879 - Dermatologic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(2Z)-4-[(1R,3aS,5S,14aS)-8-hydroxy-3,3,11,11-tetramethyl-13-(3-methylbut-2-en-1-yl)-7,15-dioxo-5,7-dihydro-3H,11H-1,5-methanofuro[3,4-g]pyrano[3,2-b]xanthen-3a(4H)-yl]-2-methylbut-2-enoic acid
7-Amino-1-(5-nitro-2-furyl)-1,8-dioxo-11,14,17,20,23-pentaoxa-2-azahexacosan-26-amide
(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-14-[(4-methylphenyl)sulfonylamino]-11-oxo-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-14-[(4-methylphenyl)sulfonylamino]-11-oxo-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-14-[(4-methylphenyl)sulfonylamino]-11-oxo-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-14-[(4-methylphenyl)sulfonylamino]-11-oxo-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-14-[(4-methylphenyl)sulfonylamino]-11-oxo-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-14-[(4-methylphenyl)sulfonylamino]-11-oxo-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
2-[(3R,6aR,8S,10aR)-1-(2-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-(4-benzylpiperidin-1-yl)ethanone
N-[(2R,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
2-[(3S,6aS,8R,10aS)-1-(2-fluorophenyl)sulfonyl-3-hydroxy-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-1-[4-(phenylmethyl)-1-piperidinyl]ethanone
[(1S)-7-methoxy-9-methyl-2-(4-methylphenyl)sulfonyl-1-(3-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
N-[(2R,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-(dimethylamino)butanamide
N-[(2S,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-(dimethylamino)butanamide
N-[(2S,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-(dimethylamino)butanamide
N-[(2S,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-(dimethylamino)butanamide
N-[(2R,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-(dimethylamino)butanamide
N-[(2S,3R)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-(dimethylamino)butanamide
N-[(2R,3S)-2-[[benzenesulfonyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-4-(dimethylamino)butanamide
N-[(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
N-[(2S,3S)-2-[[1,3-benzodioxol-5-ylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-4-pyridinecarboxamide
(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-14-[(4-methylphenyl)sulfonylamino]-11-oxo-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-14-[(4-methylphenyl)sulfonylamino]-11-oxo-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
[(1R)-7-methoxy-9-methyl-2-(4-methylphenyl)sulfonyl-1-(3-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]methanol
methyl (2R)-2-[(1S,2R,4S,5R,9R,10R,14S,15S,17S)-17-acetyloxy-9-(furan-3-yl)-1-hydroxy-10,14,16,16-tetramethyl-7,18-dioxo-3,8-dioxapentacyclo[12.3.1.02,4.04,13.05,10]octadecan-15-yl]-2-hydroxyacetate
Sotorasib
A pyridopyrimidine that is pyrido[2,3-d]pyrimidin-2(1H)-one substituted by 4-methyl-2-(propan-2-yl)pyridin-3-yl, (2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl, fluoro and 2-fluoro-6-hydroxyphenyl groups at positions 1, 4, 6 and 7, respectively. It is approved for the treatment of patients with non-small cell lung cancer having KRAS(G12C) mutations. D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors[1][2]. Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].
Protoporphyrin(2-)
C34H32N4O4 (560.2423431999999)
The dicarboxylate anion of protoporphyrin, obtained by deprotonation of both carboxy groups.
K-Ras G12C-IN-4
C31H33ClN4O4 (560.2190208000001)
K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRASG12C[1].